Lung cancer patients live longer if they use beta-blockers while receiving radiotherapy

January 8, 2013 in Cancer

Patients with non-small-cell lung cancer survive longer if they are taking beta-blockers while receiving radiotherapy, according to a study of 722 patients published in the cancer journal Annals of Oncology today.

Researchers at the University of Texas MD Anderson Cancer Center (Houston, USA) reviewed the progress and outcomes of who had received radiotherapy as their main or first line of treatment for cancer (known as "definitive radiotherapy" i.e. radiotherapy that is delivered at doses of 60 Gy or more, with the intention of curing the disease).

They found that 155 patients who were on beta-blockers for other conditions, such as and heart disease, survived for an average of 23.7 months compared to the 567 patients who were not on beta-blockers, who survived for an average of 18.6 months – an improvement in of 22% after adjusting for other factors such as age, stage of the disease, whether or not chemotherapy was given at the same time, and the use of aspirin.

Beta-blocker use was also associated with improvements in survival without the disease spreading to other parts of the body (distant metastasis-free survival) and survival without the disease recurring (disease-free survival). Beta-blockers made no difference in the length of time a patient survived without the disease progressing in the part of the lungs where it had first occurred (locoregional progression-free survival).

Assistant Professor Dr Daniel Gomez, at the Department of Radiation Oncology at the MD Anderson Cancer Center, said: "Despite recent improvements in radiotherapy and chemotherapy for non-small-cell-lung cancer, the prognosis of this disease is poor, with less than 15% of patients surviving for five years after diagnosis. A major cause of death is the process of metastasis, when travel from the original tumour to other parts of the body. Therefore, we urgently need to find new ways of blocking the development of metastases in these patients.

"Our results suggest that the use of beta-blockers during radiotherapy may help to prevent the formation of metastases, and could lead directly or indirectly to improved care for patients with . As far as we are aware, our study is the first analysis to show a survival benefit associated with the use of beta-blockers during definitive radiotherapy in patients with NSCLC. However, prospective studies are needed to investigate these findings further and to discover whether improved survival is affected by when and for how long patients need to take beta-blockers. We are excited about using our study as a starting point for further investigations."

The mechanism underlying the development of metastases is complex, but may involve chronic stress conditions and prolonged exposure to stress hormones. One of these hormones, norepinephrine, has been shown to stimulate the migration of tumour cells to other parts of the body. Receptors on the surface of cells, which beta-blockers are designed to inhibit, are involved in this process.

Professor Zhongxing Liao, from the Department of at the MD Anderson , said: "Our findings agree with results from previous studies suggesting that beta-blockers have a specific effect on the cascade of events that lead to metastases. The fact that their use did not affect locoregional progression-free survival suggests that the drugs affect this metastatic cascade rather than the primary tumour."

Patients in the study had been treated with definitive radiotherapy from 1998 to 2010 at the MD Anderson Center. The 155 patients on beta-blockers were taking a range of different types of the drug and at a range of doses depending on the medication and their need. The researchers said there were not enough patients in the study to discover whether the choice of beta-blocker might be important, but that most of the study patients who did well were on a selective beta-blocker. "This finding requires further investigation," said Prof Liao.

She added: "Due to practical limitations, we were unable to assess whether any other medications that patients were taking while receiving radiotherapy may have influenced the results. This should be the subject of future analyses, ideally in clinical trials."

Dr Gomez said the researchers were discussing the possibility of a clinical trial to investigate the efficacy of new treatments, such as beta-blockers, for , but that this would require external funding. "Another future direction would be to examine further the molecular characteristics that lead to this apparent clinical improvement in survival. For instance, what cellular pathways are involved in patients that experience a benefit with beta-blockers, and can these mechanisms be altered in another way to achieve the same benefit?"

More information: "Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy", by H.M. Wang, Z.X. Liao, R. Komaki, J.W. Welsh, M.S. O'Reilly, J.Y. Chang, Y. Zhuang, L.B. Levy, C. Lu and D.R. Gomez. Annals of Oncology. doi:10.1093/annonc/mds616

Journal reference: Annals of Oncology search and more info website

Provided by European Society for Medical Oncology search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Small increase in cancer risk following CT scans in childhood and adolescence

Study leader, Professor John Mathews from the University of Melbourne said this small increase in cancer risk must be weighed against the undoubted benefits from CT scans in diagnosing and monitoring disease.

Cancer created 4 hours ago | popularity not rated yet | comments 0

Cancer survivors need more support to stop smoking and drinking

Cancer survivors are no more likely to stop smoking, cut down on alcohol, or exercise more often than the general population, according to new research published in the British Journal of Cancer today (Wednesday)

Cancer created 5 hours ago | popularity not rated yet | comments 0

Beta-blockers may boost chemo effect in childhood cancer

Beta-blockers, normally used for high blood pressure, could enhance the effectiveness of chemotherapies in treating neuroblastoma, a type of children's cancer, according to a new study published in the British Jo ...

Cancer created 6 hours ago | popularity not rated yet | comments 0

Japan hospital tests powerful breast cancer therapy

A Japanese cancer specialist said Wednesday she has started the world's first clinical trial of a powerful, non-surgical, short-term radiation therapy for breast cancer.

Cancer created 6 hours ago | popularity 5 / 5 (1) | comments 0

Small cancer risk following CT scans in childhood and adolescence confirmed

The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...

Cancer created 19 hours ago | popularity not rated yet | comments 0


Researchers complete largest genetic sequencing study of human disease

Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.

Slowing the aging process—only with antibiotics

Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.

Research shows how immune system peacefully co-exists with 'good' bacteria

The human gut is loaded with commensal bacteria – "good" microbes that, among other functions, help the body digest food. The gastrointestinal tract contains literally trillions of such cells, and yet the ...

AIDS scientists optimistic of AIDS cure, for some

Top AIDS scientists were optimistic Wednesday of finding a cure for the disease that has claimed 30 million lives—but said it might not work for all people.

Signs of motor disorders can appear years before disease manifestation

It is known that signs of neurological disorders such as Alzheimer's and Huntington's disease can appear years before the disease becomes manifest; these signs take the form of subtle changes in the brain and behavior of ...

Fish oil supplements may help fight against Type 2 diabetes

Widely-used fish oil supplements modestly increase amounts of a hormone that is associated with lower risk of diabetes and heart disease, according to a study accepted for publication in The Endocrine Society's Journal of ...